Antonio Bedalov

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi Telomere length as a quantitative trait: genome-wide survey and genetic mapping of telomere length-control genes in yeast
    Tonibelle Gatbonton
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Genet 2:e35. 2006
  2. ncbi Neuroscience. NAD to the rescue
    Antonio Bedalov
    Clinical Research Division and J. A. Simon is in the Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Science 305:954-5. 2004
  3. ncbi NAD+-dependent deacetylase Hst1p controls biosynthesis and cellular NAD+ levels in Saccharomyces cerevisiae
    Antonio Bedalov
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Mol Cell Biol 23:7044-54. 2003
  4. ncbi Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast
    Maki Hirao
    Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Biol Chem 278:52773-82. 2003
  5. ncbi Yeast as a model system for anticancer drug discovery
    Julian A Simon
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Nat Rev Cancer 4:481-92. 2004
  6. ncbi Hst3 is regulated by Mec1-dependent proteolysis and controls the S phase checkpoint and sister chromatid cohesion by deacetylating histone H3 at lysine 56
    Safia Thaminy
    Clinical Research Division and Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Biol Chem 282:37805-14. 2007
  7. ncbi Identification and characterization of Sir2 inhibitors through phenotypic assays in yeast
    Jeff Posakony
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Comb Chem High Throughput Screen 7:661-8. 2004
  8. ncbi Substrate-specific activation of sirtuins by resveratrol
    Matt Kaeberlein
    Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA
    J Biol Chem 280:17038-45. 2005
  9. ncbi Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes
    Birgit Heltweg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Res 66:4368-77. 2006
  10. ncbi Sir2 flexes its muscle
    Antonio Bedalov
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D2-100, Seattle, WA 98107, USA
    Dev Cell 5:188-9. 2003

Research Grants

  1. Development of cambinol analogues as antilymphoma agents
    Antonio Bedalov; Fiscal Year: 2009
  2. Development of cambinol analogues as antilymphoma agents
    Antonio Bedalov; Fiscal Year: 2010

Collaborators

  • Julian Simon
  • M Kaeberlein
  • STANLEY H FIELDS
  • Brian Kennedy
  • Andrew Napper
  • Guri Giaever
  • Jeff Posakony
  • Tonibelle Gatbonton
  • Benjamin Newcomb
  • Maki Hirao
  • Eric Foss
  • John R Chevillet
  • Anthony Arnoldo
  • Eric J Foss
  • Safia Thaminy
  • Leonid Kruglyak
  • Douglas M Ruderfer
  • Birgit Heltweg
  • Melisa Nelson
  • A Rod Merrill
  • Corey Nislow
  • Vincent T Lee
  • Saranya Kittanakom
  • Valeri I Vasioukhin
  • Igor Chevelev
  • Igor Stagljar
  • Rod A Merrill
  • Becky Koscik
  • Jasna Curak
  • Lana Ljuma
  • Stephen Lory
  • Gemma J Park
  • Mehdi Sahebol-Amri
  • Peter J Roy
  • Dragan Radulovic
  • Scott A Shaffer
  • David R Goodlett
  • Jessica Kim
  • Joshua M Akey
  • Yansong Gu
  • Hongzhe Li
  • Ramya Kollipara
  • Sondra Goehle
  • Ronald A Depinho
  • Aaron D Schuler
  • Maria Imbesi
  • Sam Stevens
  • Jeffrey Posakony
  • Manfred Jung
  • Henning Hruby

Detail Information

Publications16

  1. ncbi Telomere length as a quantitative trait: genome-wide survey and genetic mapping of telomere length-control genes in yeast
    Tonibelle Gatbonton
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Genet 2:e35. 2006
    ..Furthermore, our results laid the foundation for studying genetic determinants of telomere length-variation and their roles in human disease...
  2. ncbi Neuroscience. NAD to the rescue
    Antonio Bedalov
    Clinical Research Division and J. A. Simon is in the Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Science 305:954-5. 2004
  3. ncbi NAD+-dependent deacetylase Hst1p controls biosynthesis and cellular NAD+ levels in Saccharomyces cerevisiae
    Antonio Bedalov
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Mol Cell Biol 23:7044-54. 2003
    ..These findings suggest that Hst1p serves as a cellular NAD(+) sensor that monitors and regulates cellular NAD(+) levels...
  4. ncbi Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast
    Maki Hirao
    Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Biol Chem 278:52773-82. 2003
    ..Selectivity was affirmed using whole-genome DNA microarray analysis. This study underscores the power of phenotypic screens in the development and characterization of selective inhibitors of enzyme functions...
  5. ncbi Yeast as a model system for anticancer drug discovery
    Julian A Simon
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Nat Rev Cancer 4:481-92. 2004
  6. ncbi Hst3 is regulated by Mec1-dependent proteolysis and controls the S phase checkpoint and sister chromatid cohesion by deacetylating histone H3 at lysine 56
    Safia Thaminy
    Clinical Research Division and Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Biol Chem 282:37805-14. 2007
    ..Both S phase checkpoint and SCC defects are phenocopied by H3K56 point mutants. Our findings demonstrate that Hst3-regulated H3K56 acetylation safeguards genome stability by controlling the S phase DNA damage response and promoting SCC...
  7. ncbi Identification and characterization of Sir2 inhibitors through phenotypic assays in yeast
    Jeff Posakony
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Comb Chem High Throughput Screen 7:661-8. 2004
    ....
  8. ncbi Substrate-specific activation of sirtuins by resveratrol
    Matt Kaeberlein
    Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA
    J Biol Chem 280:17038-45. 2005
    ..In light of these findings, the mechanism accounting for putative longevity effects of resveratrol should be reexamined...
  9. ncbi Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes
    Birgit Heltweg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Res 66:4368-77. 2006
    ..Cambinol was well tolerated in mice and inhibited growth of Burkitt lymphoma xenografts. Inhibitors of NAD-dependent deacetylases may constitute novel anticancer agents...
  10. ncbi Sir2 flexes its muscle
    Antonio Bedalov
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D2-100, Seattle, WA 98107, USA
    Dev Cell 5:188-9. 2003
    ....
  11. ncbi Inhibitors of Sir2: evaluation of splitomicin analogues
    Jeff Posakony
    Clinical Research and Human Biology Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA
    J Med Chem 47:2635-44. 2004
    ..Lactone hydrolysis rates were used as a measure of reactivity; hydrolysis rates correlate with inhibitory activity. The most potent Sir2 inhibitors were structurally similar to and had hydrolysis rates similar to 1...
  12. ncbi Pharmacogenetics: yeast lead the way
    Eric Foss
    Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington 98109, USA
    Chem Biol 13:236-8. 2006
    ..Their results suggest that drug responses are regulated by a limited number of loci, and that this system can identify clusters of functionally similar molecules...
  13. ncbi Genetic basis of proteome variation in yeast
    Eric J Foss
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Nat Genet 39:1369-75. 2007
    ..Loci that influenced protein abundance differed from those that influenced transcript levels, emphasizing the importance of direct analysis of the proteome...
  14. ncbi Identification and characterization of small-molecule inhibitors of hepsin
    John R Chevillet
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N C3 168, Seattle, WA 98109 1024, USA
    Mol Cancer Ther 7:3343-51. 2008
    ..These compounds may be used as leads to develop even more potent and specific inhibitors of hepsin to prevent prostate cancer progression and metastasis...
  15. ncbi Identification of inhibitors of chromatin modifying enzymes using the yeast phenotypic screens
    Benjamin Newcomb
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Methods Mol Biol 548:145-60. 2009
    ..These phenotypic assays, amenable for high throughput small molecule screening, enable identification and characterization of inhibitors of chromatin modifying enzymes largely bypassing traditional biochemical approaches...
  16. ncbi Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen
    Anthony Arnoldo
    Terrence Donnelly Centre for Cellular and Biomolecular Research, Department of Biochemistry, University of Toronto, Ontario, Canada
    PLoS Genet 4:e1000005. 2008
    ..Taken together, our integrated cell-based, chemical-genetic approach demonstrates that such screens can augment traditional drug screening approaches and facilitate the discovery of new compounds against a broad range of human pathogens...

Research Grants4

  1. Development of cambinol analogues as antilymphoma agents
    Antonio Bedalov; Fiscal Year: 2009
    ..Our goal is to use the tools of medicinal chemistry, protein crystallography, biochemistry and cell biology to develop potent and selective inhibitors of SIRT1 as anti-lymphoma drugs. ..
  2. Development of cambinol analogues as antilymphoma agents
    Antonio Bedalov; Fiscal Year: 2010
    ..Our goal is to use the tools of medicinal chemistry, protein crystallography, biochemistry and cell biology to develop potent and selective inhibitors of SIRT1 as anti-lymphoma drugs. ..